DoW Multiple Sclerosis Clinical Trial Award
Department of Defense
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level: • Funding Level 1 (CTA-FL1)
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Closing this month
Posted
05/05/2026
Closes
2026-08-13
Eligibility
Eligibility
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Program
Funding area
Science and Technology and other Research and Development - ST
Opportunity #
HT942526MSRPCTA
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov